Israel's life sciences sector is celebrated for its academic excellence and extensive basic R&D coming out of the likes of world-renowned establishments such as the Weizmann Institute and the Hebrew University of Jerusalem. There has historically been a lack of homegrown leadership to establish companies that can bridge the gap between discovery and getting products into late-stage trials, but this it is changing.
Someone well-equipped to see how the sector is developing and how companies are being created is Anat Naschitz, a managing director at health care investment firm OrbiMed, which is currently...